Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-Tumor05 and CAR-Tumor M01 in Advanced Malignant Solid Tumors
NCT07859462Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-Tumor 05 and CAR-Tumor M01 in solid tumor (advanced stage) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Dose-Limiting Toxicity at 3 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CAR-Tumor 05CAR-Tumor M01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07859462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859462.